Group One Trading’s Enveric Biosciences ENVB Stock Holding History

Group One Trading’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2	Closed	-$4K	–	7689
2022 Q2	$4K	Hold	2	–	–	﹤0.01%	7187
2022 Q1	$7K	Hold	2	–	–	﹤0.01%	7288
2021 Q4	$17K	Buy	+2	New	+$28.1K	﹤0.01%	7055

Other funds holding ENVB

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Group One Trading's ENVB Position: Q2 2026 in Review

Group One Trading sold out of Enveric Biosciences (ENVB) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Group One Trading first reported a position in ENVB in Q4 2021 and held it in 16 quarters. The position peaked at $49K in Q4 2021. 24 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

Group One Trading reported no remaining Enveric Biosciences position as of Q2 2026 after selling out during the quarter.
Group One Trading sold 1 Enveric Biosciences share in Q2 2026, an estimated $2.
Group One Trading first reported a position in Enveric Biosciences in Q4 2021 and held it in 16 quarters.
Group One Trading's Enveric Biosciences position peaked at $49K in Q4 2021.
24 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.